The impact of positive peritoneal washings and serosal and adnexal involvement on survival in patients with Stage IIIA uterine cancer

Gynecologic Oncology

Volumn 86, Issue 3, 2002, Pages 269-273

  Preyer, Oliver ^a,b   Obermair, Andreas ^a,b   Formann, Elisabeth ^b   Schmid, Werner ^b   Perrin, Lewis C ^b   Ward, Bruce G ^b   Crandon, Alexander J ^b   Nicklin, James L ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Prognostic factor; Staging; Uterine cancer

Indexed keywords

ADENOCARCINOMA; ADNEXA DISEASE; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST; ENDOMETRIOID CARCINOMA; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PERITONEAL WASHING; PRIORITY JOURNAL; PROGNOSIS; SEROSA; STATISTICAL ANALYSIS; UTERUS CARCINOMA; UTERUS SARCOMA;

EID: 0036444085     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2002.6744     Document Type: Article

References (22)

1. Creasman WT, Odicino F, Maisonneuve P, et al. International Federation of Gynecology and Obstetrics, Annual report on the results of treatment in gynecologic cancer. J Epidemiol Biostat 2001;6:45-86.
2. Greven KM, Lanciano RE, Corn B, Case D, Randall ME. Pathologic stage III endometrial carcinoma. Cancer 1993;71:3697-702.
3. Wolfson AH, Sightler SE, Markoe AM, et al. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol 1992;45:142-6.
4. International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecologic cancer. Int J Gynecol Obstet 1989;28:189-90.
5. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1985;53:457-81.
6. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
7. Connell PP, Rotmensch J, Waggoner S, Mundt AJ. The significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol 1999;74: 74-9.
8. Zerbe MJ, Bristow R, Grumbine FC, Montz FJ. Inability of preoperative computed tomography scans to accurately predict the extend of myometrial invasion and extracorporal spread in endometrial cancer. Gynecol Oncol 2000;78:67-70.
9. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
10. Chen SS. Extrauterine spread in endometrial carcinoma clinically confined to the uterus. Gynecol Oncol 1985;21:23-31.
11. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. Cancer 1987;60:2035-41.
12. Zuna RE, Behrens A. Peritoneal washing cytology in gynecologic cancers: Long-term follow-up of 355 patients. J Natl Cancer Inst 1996;88:980-7.
13. Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 1992;46:145-9.
14. Eltabbakh GH, Piver MS, Hempling RE, Shin KH. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: Report of a prospective trial. Int J Radiat Oncol Biol Phys 1997;38:373-80.
15. Hirai Y, Takeshima N, Kato T, Hasumi K. Malignant potential of positive peritoneal cytology in endometrial cancer. Obstet Gynecol 2001;97:725-8.
16. Grigsby PW, Perez CA, Kuske RR, Kao MS, Galakatos AE. Results of therapy, analysis of failures, and prognostic factors for clinical and pathological stage III adenocarcinoma of the endometrium. Gynecol Oncol 1987;27:44-57.
17. Ashman JB, Connell PP, Yamada D, Rotmensch J, Waggoner SE, Mundt AJ. Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol 2001;82:338-43.
18. Chan JK, Lin YG, Monk BJ, Tewari K, Bloss JD, Berman ML. Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol 2001;97:707-11.
19. Brooks SE, Ahn J, Mullins CD, Baquet CR, D'Andrea A. Health care cost and utilization project analysis of comorbid illness and complications for patients undergoing hysterectomy for endometrial carcinoma. Cancer 2001;92:950-8.
20. Burke TW, Stringer CA, Morris M, et al. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 1991;40:264-7.
21. Smith MR, Peters WA, Drescher CW. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am J Obstet Gynecol 1994;170:1677-82.
22. Schorge JO, Molpus KL, Goodman A, Nikrui N, Fuller AF Jr. The effect of postsurgical therapy on stage III endometrial carcinoma. Gynecol Oncol 1996;63:34-9.